Tocilizumab treatment and outcomes in severe COVID-19 patients: Retrospective study from a tertiary care institute in western India
| Autor: | Peta RK, Panchal HP, Patel A, Parikh S, Khanikar D, Himthani N |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of Medical and Scientific Research, Vol 8, Iss S1, Pp 6-10 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2321-1326 2394-112X |
| DOI: | 10.17727/JMSR.2020/8S1-1 |
| Popis: | Background: Coronavirus disease 2019 (COVID-19) is a pandemic caused by a novel beta coronavirus severe acute respiratory syndrome coronavirus (SARS-CoV-2). The symptoms range from mild to severe in nature. The severity of respiratory symptoms is due to the cytokine storm. The tocilizumab, interleukin-6 inhibitor, can prevent the cytokine release and decrease the mortality. Patients and methods: This is a retrospective observational study of 20 COVID-19 positive cases who received tocilizumab. Results and conclusion: There were 75% males with a mean age of 47.20±9.68 years in our study. 50% had diabetes mellitus, 35% had hypertension, 5% had Chronic kidney disease, 5% had obesity and 5% had hypothyroidism. Mortality was reduced to 65% with tocilizumab administration. There was statistically significant reduction of C- reactive protein (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|